Orthofix Medical Q4 Earnings Call Highlights

3 weeks ago 13

MarketBeat

Tue, February 24, 2026 astatine 11:49 AM CST 6 min read

Orthofix Medical logo

Orthofix Medical (NASDAQ:OFIX) reported fourth-quarter 2025 results that absorption said capped a twelvemonth of “meaningful operational progress,” highlighted by continued momentum successful Bone Growth Therapies and U.S. Limb Reconstruction, improving show successful planetary spine fixation, and the company’s eighth consecutive 4th of adjusted EBITDA growth.

Chief Executive Officer Massimo Calafiore said Orthofix delivered “strong, accordant performance” successful Bone Growth Therapies (BGT) and U.S. Limb Reconstruction, portion efforts to finalize its spine commercialized transmission supported double-digit nett income maturation successful planetary spine fixation. Calafiore noted distributor transitions implemented earlier successful 2025 created “temporary pressure” successful the quarter, but said show improved meaningfully exiting Q4 and that the modulation is present mostly down the company.

→ Gold and Silver Pulled Back—Here’s Why the Bull Case Is Intact

Chief Financial Officer Julie Andrews said full planetary nett income for Q4 were $218.6 million, up 3% connected a pro forma, constant-currency ground excluding the discontinued M6 artificial disc merchandise lines. She attributed maturation to spot successful BGT and U.S. limb reconstruction.

Global spinal implants, biologics, and enabling technologies: Q4 nett income of $112.3 million. Andrews said results were supported by targeted distributor transitions successful cardinal geographies, partially offset by softness successful biologics and a strategical displacement from 7D superior income to the Voyager earn-out program. She besides noted Orthofix is inactive annualizing the interaction of a antecedently disclosed terms alteration astatine a large account.
Bone Growth Therapies: Q4 nett income of $68.3 million, up 7%. Andrews said the concern importantly outperformed the marketplace and benefited from accrued utilization and higher prescribing velocity crossed spine fusion and fracture management.
Global limb reconstruction: Q4 nett income of $38.0 million, driven by 8% U.S. growth. Andrews said the show reflects Orthofix’s absorption connected halfway limb reconstruction “pillars” and a deliberate de-emphasis of products not aligned with the strategy.

Management repeatedly emphasized changes to the spine distributor network. Calafiore said Orthofix’s apical 30 U.S. distributor partners grew nett income 25% year-over-year successful Q4 and 27% connected a trailing 12-month basis, which helium described arsenic validation of the transmission strategy. He besides said that arsenic of Q4 2025, much than 75% of U.S. nett income were driven by the apical 30 distributor partners, compared with “less than a half” astatine the commencement of 2024.

Read Entire Article